Efficacy and safety of rituximab in the treatment of refractory pemfigus vulgaris


Creative Commons License

TEMEL A. B., Akman-Karakas A., Ergun E., Ozkesici B., Ugurlu N., NAZLIM B., ...More

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.49, no.2, pp.117-124, 2015 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.4274/turkderm.86402
  • Journal Name: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.117-124
  • Keywords: Rituximab, pemphigus, treatment, PEMPHIGUS, THERAPY, DISORDERS, DEPLETION, DISEASES
  • Akdeniz University Affiliated: Yes

Abstract

Background and Design: Pemphigus vulgaris (PV) is a severe, chronic, potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes, associated with the loss of cell-cell adhesion and blister formation. Systemic steroids in combination with immunosuppressive agents are the mainstay of therapy in pemphigus. Rituximab, a chimeric monoclonal anti-CD20 antibody, has been tried increasingly for the treatment of PV.